Solid lipid nanoparticles: Reversal of tamoxifen resistance in breast cancer

Eskiler, Gamze Güney; Çeçener, Gülşah; Dıkmen, Gökhan; Egelí, Ünal; Tunca, Berrin

doi:10.1016/j.ejps.2018.04.040

Cited by 54 publications

(27 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, the TAM-loaded SLNs were able to obtain a more prolonged release, suggesting their suitability for use as a controlled release drug delivery system (DDS) in BC, while reducing the hepatotoxicity associated with the free drug [79]. Another recent study demonstrated that TAM-loaded SLN formulations could be effective for overcoming TAM resistance in BC therapy, through their induction of decreased cell viability of MCF7 and MCF-7 TAM-resistant cell lines [80].…”

Section: Other Nanoparticlesmentioning

confidence: 99%

Novel Tamoxifen Nanoformulations for Improving Breast Cancer Treatment: Old Wine in New Bottles

et al. 2020

View full text Add to dashboard Cite

Breast cancer (BC) is one of the leading causes of death from cancer in women; second only to lung cancer. Tamoxifen (TAM) is a hydrophobic anticancer agent and a selective estrogen modulator (SERM), approved by the FDA for hormone therapy of BC. Despite having striking efficacy in BC therapy, concerns regarding the dose-dependent carcinogenicity of TAM still persist, restricting its therapeutic applications. Nanotechnology has emerged as one of the most important strategies to solve the issue of TAM toxicity, owing to the ability of nano-enabled-formulations to deliver smaller concentrations of TAM to cancer cells, over a longer period of time. Various TAM-containing-nanosystems have been successfully fabricated to selectively deliver TAM to specific molecular targets found on tumour membranes, reducing unwanted toxic effects. This review begins with an outline of breast cancer, the current treatment options and a history of how TAM has been used as a combatant of BC. A detailed discussion of various nanoformulation strategies used to deliver lower doses of TAM selectively to breast tumours will then follow. Finally, a commentary on future perspectives of TAM being employed as a targeting vector, to guide the delivery of other therapeutic and diagnostic agents selectively to breast tumours will be presented.

show abstract

Section: Other Nanoparticlesmentioning

confidence: 99%

Novel Tamoxifen Nanoformulations for Improving Breast Cancer Treatment: Old Wine in New Bottles

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Var-SLNs were synthesized using a hot homogenization method adapted from the method described by Eskiler et al [20]. Stearic acid (50 mg) was heated and melted at 75 • C and variabilin (25 mg), dissolved in dichloromethane (1 mL) added whilst stirring to form a stearic acid-variabilin complex with a mass ratio of 2:1.…”

Section: Preparation and Characterization Of Variabilin Loaded Stearimentioning

confidence: 99%

Encapsulation of Variabilin in Stearic Acid Solid Lipid Nanoparticles Enhances Its Anticancer Activity in Vitro

et al. 2020

View full text Add to dashboard Cite

The use of natural products as chemotherapeutic agents is well established; however, many of these are associated with undesirable side effects, including high toxicity and instability. Furthermore, the development of drug resistant cancers makes the search for new anticancer lead compounds a priority. In this study, the extraction of an Ircinia sp. sponge resulted in the isolation of an inseparable mixture of (7E,12E,20Z)-variabilin (1) and (7E,12Z,20Z)-variabilin (2) and structural assignment was established using standard 1D and 2D NMR experiments. The cytotoxic activity of the compound against three solid tumour cell lines displayed moderate anti-cancer activity through apoptosis, together with a general lack of selectivity among the cancer cell lines studied. Structural assignment and cytotoxic evaluation of variabilin was complicated and further aggravated by its inherent instability. Variabilin was therefore incorporated into solid lipid nanoparticles (SLNs) and the stability and cytotoxic activity evaluated. Encapsulation of variabilin into SLNs led to a marked improvement in stability of the natural product coupled with enhanced cytotoxic activity, particularly against the prostate (PC-3) cancer cell line, with IC50 values of 87.74 μM vs. 8.94 μM for the variabilin alone and Var-SLN, respectively. Both variabilin and Var-SLN revealed comparable activity to Ceramide against the MCF-7 breast cancer cell line, revealing IC50 values of 34.8, 38.1 and 33.6 μM for variabilin, Var-SLN and Ceramide, respectively. These samples revealed no activity (>100 μM for all) against HT-29 (colon) cell lines and MCF-12 (normal breast) cell lines. Var-SLNs induced 47, 48 and 59% of apoptosis in HT-29, MCF-7 and PC-3 cells, respectively, while variabilin alone revealed 38, 29 and 29% apoptotic cells for HT-29, MCF-7 and PC-3 cell lines, respectively. The encapsulation of natural products into SLNs may provide a promising approach to overcome some of the issues hindering the development of new anticancer drugs from natural products.

show abstract

“…In addition, Annexin V and cell cycle analysis assays of tamoxifen resistant MCF7 cells and cytotoxicity assays were utilized to measure the effect of particles on cancer cells. According to the results of the experiment, the designed tamoxifen-loaded solid lipid nanoparticles may be a potential treatment against breast cancer cells [28].…”

Section: Liposomesmentioning

confidence: 99%

“…For example, a study has shown that surface modifications occur with exosomes derived from murine immature dendritic cells. Cells were designed to express the exosomal membrane protein Lamp2b, which has been fused to the ac integrin-specific iRGD peptide [28]. The exosomes isolated by electroporation were loaded with doxorubicin (Dox), and the encapsulation efficiency was determined as 20%.…”

Section: Exosomal Drug Delivery Systemsmentioning

confidence: 99%

Current aspects in treatment of breast cancer based of nanodrug delivery systems and future prospects

Allahverdiyev

Parlar

Dinparvar

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Breast cancer is one of the most common diseases worldwide. The risk of getting this disease in female is 30% and the mortality rate is 14%. The breast cancer treatment is based on surgery, chemotherapy and radiotherapy. However, an effective treatment method has not been developed. The main cause of failure in the treatment is cancer stem cells metastasis and chemo-resistance. The use of nanocarrier systems against breast cancer stem cells has great importance. Not only advantages of polymeric drug delivery systems are increasing the stability and reduce the side effects of drugs, but also they have disadvantages such as biocompatibility and long-term potential safety. However, in recent years, studies on exosomes provide several advantages. Exosomes usage as nanocarrier do not cause immunological reactions also the drug effectively transport into the cytosol of targeted cell and have more stability characteristics. Although there are studies about various nanocarrier systems in literature against breast cancer but in general, we have not found any review that brings them together and develops a systematic approach to solving the problem. This review mentions prospective new strategies based on various nanocarrier systems and emphasize the importance of exosome based on drug delivery systems in the treatment of breast cancer.

show abstract

Solid lipid nanoparticles: Reversal of tamoxifen resistance in breast cancer

Cited by 54 publications

References 26 publications

Novel Tamoxifen Nanoformulations for Improving Breast Cancer Treatment: Old Wine in New Bottles

Novel Tamoxifen Nanoformulations for Improving Breast Cancer Treatment: Old Wine in New Bottles

Encapsulation of Variabilin in Stearic Acid Solid Lipid Nanoparticles Enhances Its Anticancer Activity in Vitro

Current aspects in treatment of breast cancer based of nanodrug delivery systems and future prospects

Contact Info

Product

Resources

About